Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. - Wikidata - wikimedia - TriplyDB

Suppression of renin-angiotensin gene expression in the kidney by paricalcitol.

Suppression of renin-angiotensin gene expression in the kidney by paricalcitol.

http://www.wikidata.org/entity/Q46350273

about

Wnt/β-catenin signaling and kidney fibrosis Interplay of vitamin D, erythropoiesis, and the renin-angiotensin system Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy Vitamin D deficiency aggravates chronic kidney disease progression after ischemic acute kidney injury The world pandemic of vitamin D deficiency could possibly be explained by cellular inflammatory response activity induced by the renin-angiotensin system.Pharmacotherapy of end-stage renal disease.Vitamin d receptor activation mitigates the impact of uremia on endothelial function in the 5/6 nephrectomized rats.Vitamin D receptor-modulated Hsp70/AT1 expression may protect the kidneys of SHRs at the structural and functional levels Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system.Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats.Renin modulates HIV replication in T cells Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis?Effect of vitamin-D analogue on albuminuria in patients with non-dialysed chronic kidney disease stage 4-5: a retrospective single center study.Emerging drugs for chronic kidney disease.Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism Multiple genes of the renin-angiotensin system are novel targets of Wnt/β-catenin signaling.Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial.Vitamin d receptor activators and clinical outcomes in chronic kidney disease.Nuclear receptors in renal disease Relationship among 25-hydroxyvitamin D concentrations, insulin action, and cardiovascular disease risk in patients with essential hypertension.Beneficial effects of calcitriol on hypertension, glucose intolerance, impairment of endothelium-dependent vascular relaxation, and visceral adiposity in fructose-fed hypertensive rats.Longitudinal FGF23 and Klotho axis characterization in children treated with chronic peritoneal dialysis.Vitamin D deficiency aggravates ischemic acute kidney injury in rats.Paricalcitol for secondary hyperparathyroidism in renal transplantation.Serum vitamin D level and prehypertension among subjects free of hypertension The use of vitamin D analogues in chronic kidney diseases: possible mechanisms beyond bone and mineral metabolism.Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study.A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria.Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine.The effects of old, new and emerging medicines on metabolic aberrations in PCOS.Vitamin D receptor signaling in podocytes protects against diabetic nephropathy.Cardiorenal syndrome and vitamin D receptor activation in chronic kidney disease The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection.Vitamin D: roles in renal and cardiovascular protection.Antioxidant and renoprotective effects of paricalcitol on experimental contrast-induced nephropathy model.Vitamin D signaling pathway plays an important role in the development of heart failure after myocardial infarction.Molecular mechanism of vitamin D in the cardiovascular system HIV compromises integrity of the podocyte actin cytoskeleton through downregulation of the vitamin D receptor.Hypovitaminosis D and Associated Cardiometabolic Risk in Women with PCOS.Vitamin D receptor signaling in renal and cardiovascular protection.

P2860

Q26796624-EB524C71-8FDC-479D-ADDA-EF864C3AA8AE Q26822500-2C148F4F-C080-4B2B-B880-CFB64DE00A8B Q28258849-629A4132-7C5F-45F9-AAAD-0593982089A2 Q28542979-06712170-919A-434F-BDC9-18B8A6FD260A Q30426517-B2D37C47-53B1-424A-A519-BEBEE3A2451F Q33531889-830ACDB0-2D99-4137-9C78-AAFBB5F1DC70 Q33651819-24382F95-932B-44FE-B756-1ABB5AACFA5A Q33700836-021C2FA5-6BE8-493E-9D8B-61A0A26E3E23 Q33979345-F8F2E52C-BD18-45E9-9117-13BCB87CFEE3 Q34032089-42E69A7C-FB40-455F-9989-013572305868 Q34178612-63EB5ED7-F1E0-444A-AA13-645230EEB539 Q34245670-9CA6A508-1EBC-4961-ACB5-2A1A93B2CE59 Q34408823-B7C5953B-3DA2-431F-8138-C56E87470626 Q34420383-63A90D02-6156-4953-94F5-B272B95EA3C2 Q34719267-64D67F19-EABA-48F7-A9B9-5AE004B2BCEB Q34787805-AF746D3F-2568-4CF6-9E90-DEA70CCA647B Q34868253-866CECB3-247C-4D31-B55D-20EC4C1FB748 Q35020986-C74FAB5B-B2EE-4A97-B7CE-37A43CFA671B Q35120702-9BB445ED-79F0-42B1-965E-1E502E253267 Q35171813-E707B540-6CBE-4F72-8DF1-9DBC16F4FCD5 Q35182438-60E34DCE-A89D-4A41-BE94-8846CD3F1D9A Q35232118-02809705-07BE-4B3C-A340-5EA516F331CF Q35363191-6B4B5E23-6A19-4C04-B104-8515A9FC1586 Q35550544-4A1729AA-824F-43F1-8B5C-AF2AD8F1B559 Q35564728-074AA1BF-25D7-4B3E-8B20-2AE88C8485BF Q35573698-C170447B-9B98-49EB-8C69-87FC9F718D6C Q36091406-E6D8CDA1-41B7-4EF5-8F00-268907ADF328 Q36249817-6C1E54E5-7331-4FFC-BC0F-3EA92541047C Q36285918-88570673-903B-434E-A12C-063B628A5E35 Q36328060-C92AEE88-0BCC-40BB-B836-4A61E6707FCB Q36426113-D757DAD1-0173-40D2-8839-182AFC775394 Q36468531-073A2C30-F8C0-4061-895C-DE2A3C599702 Q36613869-931126F2-097D-453D-B436-1614B5EF03AB Q36614706-3804BE94-825A-4EF8-AAB3-D27B04D57B14 Q36653170-BCC270CB-5B92-4C89-B4F2-A67393EC8C4C Q36787402-B4F39EC9-5BE5-4C62-A1C3-9824D5D18EDB Q36821166-AD5159EB-50BF-4B95-BDF3-547151C838D4 Q36923668-9A443A1A-078E-4044-A38C-0C221A8374C6 Q37102543-DE5FAE4E-AF28-4495-96CC-B5B21CCE20DF Q37230136-47938FA0-363A-464E-85CA-9FE352322246

P2860

Suppression of renin-angiotensin gene expression in the kidney by paricalcitol.

http://www.wikidata.org/entity/Q46350273

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Suppression of renin-angiotensin gene expression in the kidney by paricalcitol.

@en

Suppression of renin-angiotensin gene expression in the kidney by paricalcitol.

@nl

type

label

Suppression of renin-angiotensin gene expression in the kidney by paricalcitol.

@en

Suppression of renin-angiotensin gene expression in the kidney by paricalcitol.

@nl

prefLabel

Suppression of renin-angiotensin gene expression in the kidney by paricalcitol.

@en

Suppression of renin-angiotensin gene expression in the kidney by paricalcitol.

@nl

P1433

Q46350273-AE3C121E-04C3-49DB-84AD-E69DAAF992EC

P1476

Q46350273-4DDAC828-4E7A-4FE9-8DA0-C65977E78D51

P2093

Q46350273-0C3524B5-4897-454F-A6F5-E43B68898723

Q46350273-4A6D0C2B-82D4-4A14-B13B-2CE9F5CD117F

Q46350273-4EE3EDA4-3552-406B-A12B-C82FD8337265

Q46350273-B4DD4E62-3E2B-4E6C-9A4A-DA1852613ACD

Q46350273-BA7BBB73-2085-4E83-B92E-D58D729EA3C6

Q46350273-CFB1F1CD-D950-4046-8F19-D8AA719421D0

Q46350273-ED61AB13-FDDA-460A-B3BE-7FFE1B7F6565

Q46350273-F947AE84-7526-4D66-B3A6-4290BBD07F59

P2888

Q46350273-4A7C9980-EBE1-40B6-A727-E13905A0A775

P304

Q46350273-28BC6C5A-FB74-47AC-A147-83BC4C90EB1A

P31

Q46350273-BA3D64BC-F020-435E-8E06-A0CF9689852A

P356

Q46350273-6602026C-B9F1-44E2-A58C-4660842FD654

P407

Q46350273-407FF763-57F9-4657-9624-B14826809666

P433

Q46350273-93C6F767-EC2F-4E65-BBE8-05B1DEF7B00B

P478

Q46350273-D021C90E-C623-44A3-BE64-44158E54F01B

P577

Q46350273-F9BE3C00-59CD-4D88-933C-97F5DA9E9A45

P5875

Q46350273-0F43B8AE-02F2-472C-8AFD-43F4C28AD4F6

P698

Q46350273-C39E18DA-DDEC-4D05-86D7-730ACF735B1E

P356

P1433

Kidney International

P1476

Suppression of renin-angiotensin gene expression in the kidney by paricalcitol.

@en

P2093

Bernardo Rodriguez-Iturbe

http://www.w3.org/2001/XMLSchema#string

Jose R Weisinger

http://www.w3.org/2001/XMLSchema#string

Michael Freundlich

http://www.w3.org/2001/XMLSchema#string

Yan Chun Li

http://www.w3.org/2001/XMLSchema#string

Yan Zhang

http://www.w3.org/2001/XMLSchema#string

Yanauri Bravo

http://www.w3.org/2001/XMLSchema#string

Yasmir Quiroz

http://www.w3.org/2001/XMLSchema#string

Zhongyi Zhang

http://www.w3.org/2001/XMLSchema#string

P2888

P304

1394-1402

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/KI.2008.408

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23279282

http://www.w3.org/2001/XMLSchema#string

P698

18813285

http://www.w3.org/2001/XMLSchema#string